About
Care and conscience are
the core of our corporate values
more
the core of our corporate values
03 Sep,2021
Zylox-Tonbridge Sets up Beijing Office and Shanghai R&D Center to Attract High-Quality Talents and Strive for Rapid Development
Zylox-Tonbridge (2190.HK) recently announced that it has respectively set up an office in Beijing and a R&D center in Shanghai to attract more outstanding industry talents and promote the rapid an...
more
15 Jul,2021
Zylox-Tonbridge completes patient enrollment in the PEVENSEY study for Zynlastic™ peripheral venous stent system
On July 12, 2021, ZYLOX-TONBRIDGE (2190.HK) announced that the Company has successfully completed enrollment in the PEVENSEY study. The PEVENSEY study is a prospective multicenter randomized controlle...
more
02 Jul,2021
Zylox-Tonbridge Brings a New Option for Overseas Patients with Acute Ischemic Stroke
Zylox-Tonbridge is launching the CYLONE™ Aspiration Catheter in the global market. After introducing the Thrombite™ Clot Retriever Device last year, Zylox-Tonbridge brings again a new option for pat...
more
27 Apr,2021
2021 ZYLOX-TONBRIDGE INDUSTRIAL PARK OPENING CEREMONY
On 27th April 2021, the opening ceremony of ZYLOX-TONBRIDGE Industrial Park was held grandly.The park was completed and put into use on April 10th, 2021, covering an area of nearly 23 acres. The park ...
more
08 Mar,2021
TonBridge Medical was selected as a technology-based SMEs in Guangdong
In March 2021, Zhuhai TonBridge Medical Technology Co., Ltd. was once again selected as a technology-based SMEs in Guangdong successfully. So far, TonBridge Medical has been in the list technology-bas...
more
04 Jan,2021
SWEDEPAD Interim Analysis Shows No Mortality Difference Found for Paclitaxel-Coated Devices.
On December 9, 2020, the New England Journal of Medicine published an article based on the findings from the Swedish Drug Elution Trial in Peripheral Arterial Disease (SWEDEPAD). The SWEDEPAD trial is...
more
